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ABSTRACT The mRNA-destabilizing factor tristetraprolin (TTP) binds in a sequence-
speciﬁc manner to the 3= untranslated regions of many proinﬂammatory mRNAs and
recruits complexes of nucleases to promote rapid mRNA turnover. Mice lacking TTP
develop a severe, spontaneous inﬂammatory syndrome characterized by the overex-
pression of tumor necrosis factor and other inﬂammatory mediators. However, TTP
also employs the same mechanism to inhibit the expression of the potent anti-
inﬂammatory cytokine interleukin 10 (IL-10). Perturbation of TTP function may there-
fore have mixed effects on inﬂammatory responses, either increasing or decreasing
the expression of proinﬂammatory factors via direct or indirect mechanisms. We re-
cently described a knock-in mouse strain in which the substitution of 2 amino acids
of the endogenous TTP protein renders it constitutively active as an mRNA-destabilizing
factor. Here we investigate the impact on the IL-10-mediated anti-inﬂammatory re-
sponse. It is shown that the gain-of-function mutation of TTP impairs IL-10-mediated
negative feedback control of macrophage function in vitro. However, the in vivo ef-
fects of TTP mutation are uniformly anti-inﬂammatory despite the decreased expres-
sion of IL-10.
KEYWORDS dual-speciﬁcity phosphatase 1, inﬂammation, macrophages,
posttranscriptional RNA-binding proteins, tristetraprolin
Macrophages are at the forefront of innate immune-mediated defenses againstinfectious pathogens. They are equipped with several pattern recognition recep-
tors (PRRs) with which they detect pathogen-associated molecular patterns (PAMPs)
common to different classes of microbes, for example, lipopolysaccharide (LPS), a
component of the cell wall of Gram-negative bacteria (1, 2). The engagement of
macrophage PRRs initiates very rapid changes of gene expression in order to mobilize
antimicrobial effectors, recruit and/or activate other cells of the innate and acquired
immune systems, amplify danger signals, and coordinate effective cellular responses.
Excessive responses of macrophages to the engagement of PRRs is potentially harmful,
in the worst case leading to systemic organ failure and death. It is therefore unsurpris-
ing that macrophage activation by PAMPs is regulated by complex networks of positive
and negative feedback mechanisms that together ensure rapid but proportional and
temporally limited proinﬂammatory responses (3–7).
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One important feedback mechanism involves the secretion of the anti-inﬂammatory
cytokine interleukin 10 (IL-10). Particularly in tissues like those of the gut, which are
continuously exposed to PAMPs, IL-10 is essential for restraining inﬂammatory re-
sponses to commensal microorganisms (8, 9). One critical function of IL-10 is the
suppression of the Il12b gene, which codes for the shared p40 subunit of the cytokines
IL-12 and IL-23. The constraint of IL-12 and IL-23 expression is required to prevent
excessive Th1- and Th17-mediated intestinal inﬂammation (10–13). Macrophage-
speciﬁc knockout of the IL-10 receptor (IL-10R) results in severe spontaneous gut
inﬂammation (14, 15). Similarly, polymorphisms in the human IL-10–IL-10R axis are
associated with susceptibility to inﬂammatory bowel disease (16). The anti-inﬂammatory
actions of IL-10 are mediated by the transcription factor STAT3 (signal transducer and
activator of transcription 3), which is phosphorylated and activated by the tyrosine
kinases JAK1 and TYK2 upon the engagement of the IL-10 receptor. A number of
STAT3-regulated target genes have been implicated as mediators of anti-inﬂammatory
functions of IL-10 (6, 17–19). The other side of the coin is that increased expression of
IL-10 may contribute to pathogenesis, for example, by impairing antitumor immunity
(20). Several viruses express IL-10 orthologues, apparently as a means of evasion of the
innate immune system (21). The expression of endogenous IL-10 is tightly regulated by
different mechanisms in several cell types that can express this anti-inﬂammatory
cytokine (22, 23).
Much is known about how transcription factors regulate the complex programs of
gene expression in activated macrophages (3, 24–27). It is often overlooked that the
dynamic regulation of mRNA stability also plays an important role (28, 29). Many
inﬂammatory mediator mRNAs have adenosine/uridine-rich elements (AREs) in their 3=
untranslated regions, which act as binding sites for various RNA-destabilizing factors,
the best characterized of which is tristetraprolin (TTP) (30, 31). TTP promotes the rapid
turnover of its substrate transcripts by recruiting a number of nuclease complexes,
notably the CCR4/NOT complex, which mediates poly(A) tail shortening, the rate-
limiting step in the degradation of most mRNA species. In resting macrophages, TTP is
expressed at very low levels. Its upregulation in response to proinﬂammatory stimuli
constitutes a negative feedback mechanism to limit the duration and strength of
inﬂammatory gene expression (30–32). Myeloid cell-speciﬁc disruption of the TTP gene
(formally known as Zfp36) causes extreme sensitivity to lethal endotoxic shock, al-
though there is no evident phenotype in the absence of inﬂammatory challenge (33,
34). In contrast, global disruption of the Zfp36 gene causes a spontaneous and severe
inﬂammatory syndrome with some features of rheumatoid arthritis (35). Tnf was the
ﬁrst mRNA shown to be posttranscriptionally regulated by TTP, and dysregulation of
tumor necrosis factor (TNF) expression plays an important role in both myeloid cell-
speciﬁc and global Zfp36 knockout phenotypes (33–36). Nevertheless, it is clear that
very many additional targets exist and are dysregulated in cells lacking TTP (30, 37, 38).
Puzzlingly, IL-10 was identiﬁed as a target of posttranscriptional regulation by TTP,
which was overexpressed by Zfp36/macrophages (38–41). Enhanced IL-10-mediated
negative feedback in Zfp36/ cells resulted in the paradoxical underexpression of IL-6,
IL-12, and IL-23 (39, 41).
The mitogen-activated protein kinase (MAPK) p38 signaling pathway controls the
expression of inﬂammatory mediators via the phosphorylation and inactivation of TTP
(42, 43). Hence, MAPK p38 inhibitors decrease the expression levels of several proin-
ﬂammatory mediators and destabilize the corresponding mRNAs in Zfp36/ but not
Zfp36/ macrophages (41, 44). The critical phosphorylations, at serine 52 and serine
178 of murine TTP, are carried out by MAPK-activated protein kinase 2 (MK2), which is
downstream of the MAPK p38 itself (43, 45–47). They result in the recruitment of 14-3-3
proteins, the disruption of the interaction between TTP and the CCR4/NOT complex,
and the consequent protection of the target transcript’s poly(A) tail (46, 48–50). The
coupling between MAPK p38 signaling and TTP activity contributes to the precise
timing of gene expression in activated macrophages (33, 38). Prolonged MAPK p38
activation in macrophages lacking the MAPK phosphatase dual-speciﬁcity phosphatase
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1 (DUSP1) promotes the overexpression of several inﬂammatory mediators in vitro and
in vivo, causing exaggerated responses to experimental challenges such as LPS injec-
tion (5, 51). To a large extent, this dysregulated inﬂammatory response is caused by the
increased phosphorylation and inactivation of TTP, the increased stability of proinﬂam-
matory mRNAs, and a delay to the off phase of gene expression (52).
We recently used homologous recombination to generate a knock-in mouse strain
in which Ser52 and Ser178 of the endogenous TTP protein are replaced with nonphos-
phorylatable alanine residues (53). The mutated Zfp36 locus is known as Zfp36aa, and its
protein product is known as TTPaa. Since it cannot be inactivated by the MAPK p38
pathway, TTPaa is a constitutive, dominant mRNA-destabilizing protein. Its expression
protects mice from harmful consequences of systemic LPS injection (53), experimental
inﬂammatory arthritis (54), and inﬂammatory lung pathologies (43). Differential gene
expression was assessed by microarray analysis of Zfp36aa/aa macrophages, which
express the alanine-substituted mutant form of TTP from the endogenous Zfp36 locus
(52, 53). Several known TTP target mRNAs, such as F3, Tnf, Cxcl1, Cxcl2, Ier3, and Il10,
were underexpressed by Zfp36aa/aa macrophages, and some putative novel TTP targets
were identiﬁed.
We and others have discussed the possibility of therapeutic targeting of TTP in order
to exert anti-inﬂammatory effects (31, 43). A proof of principle was generated by the
treatment of experimental arthritis using two compounds that promote PP2A-mediated
dephosphorylation and activation of TTP (54). A signiﬁcant concern is that altering TTP
function could give rise to unwanted proinﬂammatory effects by disrupting endoge-
nous negative feedback mechanisms, for example, those involving IL-10 (37, 39–41).
Here we investigated in vitro and in vivo consequences of the impaired expression of
IL-10 caused by a gain-of-function mutation of TTP.
RESULTS
Anomalous expression of certain TTP targets by Zfp36aa/aa macrophages.
Microarray analysis was performed to identify transcripts differentially expressed by
Zfp36aa/aa macrophage colony-stimulating factor (M-CSF)-differentiated bone marrow-
derived macrophages (M-BMMs) after stimulation with LPS. The microarray data were
deposited at the Gene Expression Omnibus, and some aspects of their analysis were
previously reported (52, 53). Figure 1 illustrates the analysis of LPS-induced transcripts
FIG 1 Differentially expressed transcripts in Zfp36aa/aa M-BMMs. M-BMMs were generated from 3 Zfp36/ and 3
Zfp36aa/aa mice and treated with 10 ng/ml LPS for 1 h (A) or 4 h (B). RNA was isolated, and transcript abundance
was analyzed by using Agilent microarrays and Partek Genomics Suite. Transcripts expressed above an arbitrary
threshold of 200 RMA in at least two replicates and demonstrating upregulation by LPS (2 times; P  0.05) were
selected for display. Data are illustrated in the form of volcano plots, in which transcripts with a1.5-fold difference
in expression levels between Zfp36/ and Zfp36aa/aa M-BMMs and a corrected P value of 0.05 are shaded black.
Underexpressed transcripts are to the left of the origin. Several transcripts are highlighted.
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(2-fold increase of expression in response to LPS; P  0.05). The data are presented
in the form of volcano plots, in which transcripts with a 1.5-fold difference of
expression between Zfp36/ and Zfp36aa/aa M-BMMs and a corrected P value of0.05
are shaded black. Differential expression data are summarized in Table S1 in the
supplemental material. As expected for a dominant negative regulator of gene expres-
sion, many transcripts were underexpressed by Zfp36aa/aa M-BMMs. Several of the
changes of expression at 1 h were previously reported, including the underexpression
of Tnf, Il10, and Cxcl1 mRNAs (53). By 4 h after the addition of LPS, the levels of both
Tnf and Cxcl1 mRNAs had almost returned to basal levels, and differences between
Zfp36/ and Zfp36aa/aa M-BMMs were no longer statistically signiﬁcant (also see Fig.
4A). Il10 mRNA was signiﬁcantly underexpressed by Zfp36aa/aa M-BMMs at both the 1-h
and 4-h time points. Contrary to expectation, Il6, which was previously characterized as
a TTP target (38, 41, 55, 56), was not signiﬁcantly underexpressed by Zfp36aa/aa M-BMMs
(Fig. 1). Several other transcripts were signiﬁcantly overexpressed by Zfp36aa/aa
M-BMMs. One example, Il12b, is highlighted in Fig. 1.
Gene ontology (GO) analysis was performed on transcripts differentially expressed
by Zfp36aa/aa M-BMMs (see Table S2 in the supplemental material). At both 1 h and 4
h, underexpressed transcripts were highly enriched in several GO terms relating to
response to stimulus, defense response, or inﬂammatory response. The enrichment of
these terms was a consequence of the differential expression levels of transcripts
including Tnf, Cxcl1, Cxcl2, Clcf1, Ier3, S100a8, Zfp36, Mefv, Ltf, and Il10, most of which
were previously described as TTP targets (30). These results are arguably trivial, given
that LPS-induced transcripts were selected prior to the analysis of differential gene
expression. GO analysis of the overexpressed transcripts was more informative. At 1 h,
several GO terms related to cell migration were very signiﬁcantly enriched (P  1010).
All of these enrichments arose from the increased expression levels of four transcripts,
namely, Cited2, Cxcl10, Sdc4, and Trib1. At 4 h, the most signiﬁcantly enriched GO terms
were related to the phosphorylation of the transcription factor STAT5 (signal transducer
and activator of transcription 5) or the regulation of the extrinsic apoptosis pathway
(Table S2). The corresponding lists of differentially expressed transcripts were domi-
nated by Il12b, Csf2, Cx3cl1, Kdr, and Rasip1. These ﬁndings suggest that the genes
overexpressed by Zfp36aa/aa M-BMMs are functionally distinct.
TTP can negatively regulate gene expression by inhibiting translation rather than
destabilizing mRNA (37, 57, 58). The LPS-induced expression levels of the TNF, IL-6,
IL-10, and IL-12p40 proteins between Zfp36/ and Zfp36aa/aa M-BMMs were therefore
compared. Multiple experiments were performed by using different numbers and
densities of M-BMMs, depending on whether the primary aim was to harvest RNA for
microarrays, RNA for quantitative PCR (qPCR), secreted protein for enzyme-linked
immunosorbent assays (ELISAs) and multiplex assays, or intracellular protein for West-
ern blotting. Regardless of the experimental conditions, the expression levels of both
the TNF and IL-10 proteins were consistently diminished in Zfp36aa/aa M-BMMs (by
approximately 5-fold and 3-fold, respectively) (Fig. 2A and B). In contrast, the pattern of
expression of IL-6 was inconsistent, with unchanged expression by Zfp36aa/aa M-BMMs
in most cases but both overexpression and underexpression in some experiments.
Overall, there was no statistically signiﬁcant difference in the expression levels of IL-6
between Zfp36/ and Zfp36aa/aa M-BMMs. (Fig. 2C). The expression level of the
IL-12p40 protein was invariably higher in Zfp36aa/aa than in matched Zfp36/
M-BMMs, although the extent of overexpression was quite variable (Fig. 2D).
Anomalous expression of certain TTP targets by Dusp1/ macrophages. In
Dusp1/ macrophages, enhanced and prolonged MAPK p38 activation in response to
LPS promotes the overexpression of several cytokines and chemokines via increased
phosphorylation and inactivation of TTP (52). The deﬁning characteristic of genes that
are regulated by the DUSP1-TTP axis is that the overexpression caused by the disrup-
tion of the Dusp1 gene can be prevented by combining this with the Zfp36aa/aa
genotype. Dysregulated MAPK p38 signaling fails to promote the overexpression of
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target genes if TTP cannot be phosphorylated and inactivated. At the protein and
mRNA levels, the expression levels of both TNF and the anti-inﬂammatory cytokine
IL-10 conformed to the pattern described above, being elevated in Dusp1/ but not
Dusp1/-Zfp36aa/aa M-BMMs (Fig. 3). Il6 mRNA levels were decreased in M-BMMs of all
three genetically modiﬁed genotypes, but there were no signiﬁcant differences in
protein expression levels (Fig. 3). At 4 h, the expression level of Il12bmRNA was actually
decreased rather than increased in Dusp1/ M-BMMs and was increased rather than
decreased in Zfp36aa/aa M-BMMs, whereas in Dusp1/-Zfp36aa/aa M-BMMs, the expres-
sion level of Il12b mRNA was not signiﬁcantly different from that in wild-type controls
(Fig. 3). The pattern of expression of the IL-12p40 protein was similar.
Targeted mutation of TTP paradoxically increases transcription of the Il6 and
Il12b genes. Tnf, Il6, Il10, and Il12b mRNAs can all be physically recognized by TTP (38)
yet show very different responses to mutations that inﬂuence TTP phosphorylation and
activity. To make sense of these disparate patterns, we monitored gene expression at
the levels of steady-state mRNA, primary transcripts (as a surrogate for the transcription
rate), mRNA stability, and protein secretion in LPS-treated Zfp36/ and Zfp36aa/aa
M-BMMs (Fig. 4).
The abundances of both Tnf and Il10 steady-state mRNAs were decreased in
Zfp36aa/aa M-BMMs (Fig. 4A). The expression levels of the corresponding proteins were
diminished (Fig. 4D), as previously shown (53) (Fig. 2). There were no signiﬁcant
differences in Tnf or Il10 primary transcript levels (Fig. 4B), but the stabilities of Tnf and
Il10 mRNAs were decreased in Zfp36aa/aa M-BMMs (Fig. 4C), as previously reported (53).
The behavior of both the Tnf and Il10 genes is therefore consistent with direct
regulation by TTP at the level of mRNA stability. Since the Zfp36 gene mutation had a
greater effect on the TNF and IL-10 proteins than on Tnf and Il10 mRNAs, the phos-
phorylation of TTP may also have some impact at the translational level, as was
previously suggested (37, 57, 58).
FIG 2 Expression of TNF, IL-10, IL-6, and IL-12p40 proteins by Zfp36/ and Zfp36aa/aa M-BMMs. Matched Zfp36/ and
Zfp36aa/aa M-BMMs were cultured in 24-, 12-, or 6-well dishes and stimulated with 10 ng/ml LPS for 4 h. ELISAs or multiplex
bead assays were used to measure TNF (A), IL-10 (B), IL-6 (C), and IL-12p40 (D) levels. In the cases of TNF and IL-6, 5 of 14
experiments employed matched Zfp36/ and Zfp36aa/aa littermates. All other experiments employed at least three mice of
each genotype, with mean cytokine concentrations being plotted. Cytokine quantities expressed by matched Zfp36/ and
Zfp36aa/aa M-BMMs or sets of M-BMMs are connected by lines. The graphs on the right show mean cytokine expression levels
in Zfp36aa/aa M-BMMs relative to those in matched Zfp36/ controls. n.s., not statistically signiﬁcant; ***, P  0.005; **, P 
0.01 (by a Wilcoxon matched-pair test).
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Only a minor difference in the steady-state Il6 mRNA abundance was detected at 4
h (Fig. 4A), and IL-6 secretion did not differ between Zfp36/ and Zfp36aa/aa M-BMMs
(Fig. 4D). There appeared to be an almost perfect balance between the increase in the
rate of Il6 transcription (Fig. 4B) and the increase in the rate of Il6 mRNA degradation
(Fig. 4C). Il12b mRNA was highly stable in both Zfp36/ and Zfp36aa/aa M-BMMs (Fig.
4C). The increased expression levels of Il12b mRNA (Fig. 4A) and IL-12p40 protein (Fig.
4D) by Zfp36aa/aa M-BMMs appeared to be driven by an enhanced transcriptional
response to LPS (Fig. 4B).
Disruption of IL-10-mediated negative feedback contributes to the anomalous
expression of IL-6 and IL-12p40 by Zfp36aa/aa macrophages. IL-10 is a well-
characterized target of TTP (38–41), which is underexpressed by Zfp36aa/aa M-BMMs
(Fig. 5) and known to negatively regulate the expression of TNF, IL-12p40, and IL-6 (7,
19). Noticeably, the expression of IL-12p40 in macrophages of differing genetic back-
grounds was an almost perfect mirror image of IL-10 expression (Fig. 3). It was therefore
speculated that a disruption of IL-10-mediated autocrine negative feedback mecha-
nisms contributed to differences in IL-6 and IL-12p40 expression in vitro.
It is not known whether proinﬂammatory genes display the same dose response to
inhibition by IL-10. Differential sensitivity to IL-10 could inﬂuence the outcomes of
dysregulated IL-10 biosynthesis in macrophages. Therefore, Il10/M-BMMs were used
FIG 3 Regulation of inﬂammatory mediators by DUSP1 and TTP. Wild-type, Dusp1/, Zfp36aa/aa, and
Dusp1/-Zfp36aa/aa M-BMMs were stimulated with 10 ng/ml LPS for 1 h or 4 h. Expression levels of
selected mRNAs were determined by microarray analysis (A), and the levels of the corresponding
proteins were measured by an ELISA or a multiplex bead assay (B). Graphs represent means  standard
errors of the means of data from 3 independent M-BMM cultures. n.s., not statistically signiﬁcant; *, P 
0.05; **, P  0.01; ***, P  0.005 (by one-way ANOVA). The microarray experiment used to generate the
data in panel A was previously described (52).
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to investigate the relative sensitivity of TNF, IL-12p40, and IL-6 expression to exogenous
IL-10 in the absence of interference from endogenous IL-10 (Fig. 5). The three proin-
ﬂammatory cytokines displayed quite distinct dose responses. IL-12p40 was the most
sensitive in terms of both the 50% effective concentration (EC50) (estimated to be 0.15
ng/ml) and maximal inhibition (93%). TNF was inhibited by a maximum of 76% and
with an EC50 of approximately 0.29 ng/ml. IL-6 biosynthesis was insensitive to low
FIG 4 TTP mutation affects gene expression at different levels. Zfp36/ and Zfp36aa/aa M-BMMs were treated with LPS for the times indicated,
supernatants were collected, and RNA was isolated. (A) Steady-state mRNA abundance was measured by quantitative PCR. (B) Levels of primary
transcripts were measured by quantitative PCR. (C) Actinomycin D (AmD) chase experiments were performed at the peak of gene expression (1
h in the case of Tnf and 4 h in the cases of Il10, Il6, and Il12b). (D) Levels of secreted proteins were measured by an ELISA or a multiplex bead
assay. Graphs represent means  standard errors of the means of data from three independent M-BMM cultures in each case. Pairwise
comparisons that showed no statistical signiﬁcance are not indicated. *, P  0.05; **, P  0.01; ***, P  0.005 (by a Mann-Whitney test).
FIG 5 Dose-dependent inhibition of proinﬂammatory gene expression by IL-10. Il10/ M-BMMs were
stimulated with 10 ng/ml LPS for 4 h in the presence of different concentrations of recombinant IL-10.
TNF, IL-6, and IL-12p40 levels were quantiﬁed by an ELISA. Cytokine levels were normalized against those
in the absence of IL-10. The graph shows means  standard errors of the means of data from at least
8 independent M-BMM cultures.
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concentrations of IL-10. Maximal inhibition was 81%, and the estimated EC50 was 1.52
ng/ml.
Differentiation of BMMs in the presence of granulocyte-macrophage colony-
stimulating factor (GM-CSF) rather than M-CSF has been reported to generate a cell
population (GM-BMMs) that expresses relatively little IL-10 but larger amounts of TNF,
IL-6, and IL-12p40 in response to LPS (59, 60). It was conﬁrmed that wild-type GM-BMMs
expressed 5-fold less IL-10 than did M-BMMs generated in parallel from the same donor
mice (Fig. 6). The expression levels of the proinﬂammatory cytokines TNF, IL-6, and
IL-12p40 were elevated 2.5-fold, 5.4-fold, and 56.3-fold, respectively, in GM-BMMs
compared to M-BMMs generated in parallel. Zfp36/ and Zfp36aa/aa GM-BMMs did not
differ in their expression of IL-10 after stimulation with LPS. Therefore, in GM-BMMs, the
targeted mutation of TTP cannot indirectly inﬂuence gene expression by perturbing
IL-10-mediated autocrine/paracrine feedback mechanisms. Targeted mutation of the
Zfp36 locus decreased the expression of TNF in both M-BMMs and GM-BMMs. The Zfp36
mutation did not affect IL-6 expression in M-BMMs, whereas in GM-BMMs, the mutation
signiﬁcantly decreased the expression of IL-6. The expression of IL-12p40 was elevated
as a consequence of the Zfp36mutation in M-BMMs. In contrast, in GM-BMMs, the Zfp36
mutation had no signiﬁcant effect on IL-12p40 expression.
The observations described above support the hypothesis that changes in the
expression of IL-10 inﬂuence the phenotype caused by the substitution of two TTP
FIG 6 Differential gene expression in Zfp36/ and Zfp36aa/aa M-BMMs and GM-BMMs. Macrophages
were differentiated from bone marrow of Zfp36/ and Zfp36aa/aa mice in the presence of either M-CSF
of GM-CSF and treated with 10 ng/ml LPS for 4 h. Cytokine levels were measured by an ELISA or a
multiplex bead assay. Graphs represent means  standard errors of the means from 4 independent
cultures (TNF, IL-10, and IL-12p40) or 7 independent cultures (IL-6). n.s., not statistically signiﬁcant; *, P 
0.05 (by a Mann-Whitney test).
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phosphorylation sites. To test this hypothesis more rigorously, Zfp36/ and Zfp36aa/aa
M-BMMs were stimulated with LPS in the presence of an IL-10-neutralizing antibody or
an isotype control (Fig. 7). In the presence of the neutralizing antibody, IL-6 was
underexpressed by Zfp36aa/aa M-BMMs. IL-10 neutralization increased the expression of
IL-12p40 in Zfp36/ M-BMMs but had relatively little effect on Zfp36aa/aa M-BMMs. As
a consequence, the degree of overexpression of IL-12p40 by Zfp36aa/aa M-BMMs was
diminished. Together, these data indicate that the aberrant patterns of expression of
IL-6 (unaltered in Zfp36aa/aa M-BMMs) and IL-12p40 (elevated in Zfp36aa/aa M-BMMs) are
at least partly due to alterations in IL-10-mediated negative feedback. The expression
of TNF appears minimally sensitive to this phenomenon.
Targeted mutation of TTP has overwhelmingly anti-inﬂammatory conse-
quences in vivo. Next, Zfp36/ and Zfp36aa/aa mice were injected intraperitoneally
(i.p.) with LPS, and serum cytokine and chemokine levels were measured after 3 and 12
h (Fig. 8). Decreased expression levels of TNF and IL-10 in Zfp36aa/aa mice were
previously reported (53) (indicated by † in Fig. 8). CCL3, CCL4, CCL11, CSF2, gamma
interferon (IFN-), IL-1, IL-5, and IL-13 were also signiﬁcantly underexpressed by
Zfp36aa/aa mice. Most notably, the expression level of IL-6 was decreased by almost
4-fold at 3 h and by more than 200-fold at 12 h in Zfp36aa/aa mice. The elevated
expression of IL-12p40 in LPS-treated Zfp36aa/aa M-BMMs was not recapitulated in vivo.
Serum concentrations of IL-12p40 were not signiﬁcantly different between LPS-treated
Zfp36/ and Zfp36aa/aa mice at 3 h but were signiﬁcantly lower in Zfp36aa/aa mice
at 12 h.
Finally, to test whether cytokine expression in vivo was regulated by DUSP1 via
alterations in TTP phosphorylation, wild-type, Dusp1/, Zfp36aa/aa, and Dusp1/-
Zfp36aa/aa mice were injected intraperitoneally with LPS and culled after 3 h, and the
expression levels of Tnf, Il10, Il6, and IL12b mRNAs were measured in spleens (Fig. 9).
FIG 7 Endogenous IL-10 differentially affects the expression of proinﬂammatory cytokines. Zfp36/ and
Zfp36aa/aa M-BMMs were treated with 10 ng/ml LPS for 4 h (TNF and IL-6) or 8 h (IL-12p40) in the presence
of 10 g/ml IL-10-neutralizing antibody or an isotype control. Cytokine levels were measured by a
multiplex bead assay or an ELISA. Graphs represent means  standard errors of the means from 4
independent M-BMM cultures. n.s., not statistically signiﬁcant; ***, P  0.005 (by a Mann-Whitney test).
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Levels of Tnf and Il10 mRNAs were elevated in spleens of LPS-treated Dusp1/ mice
and decreased in those of Zfp36aa/aa mice. When Dusp1/ and Zfp36aa/aa genetic
modiﬁcations were combined, the Zfp36aa/aa phenotype was dominant, and the ex-
pression levels of both mRNAs remained low. These patterns of gene expression are
very similar to those previously described in vitro (Fig. 3A) and in serum of LPS-treated
mice (52), consistent with DUSP1 regulating gene expression via modulation of the
phosphorylation state of TTP in both contexts. Strikingly, the pattern of expression of
Il6 mRNA was the same: it was increased in Dusp1/ spleens but decreased in both
Zfp36aa/aa and Dusp1/-Zfp36aa/aa spleens, indicating a similar mechanism of regula-
tion. The level of the IL-6 protein was also very strongly elevated in sera of LPS-treated
Dusp1/ mice but decreased in sera of both Zfp36aa/aa and Dusp1/-Zfp36aa/aa mice
(data not shown). Differences in the expression levels of Il12b mRNA among the four
genotypes of mice were not signiﬁcant. The dysregulation of Il12b gene expression in
isolated Zfp36aa/aa M-BMMs was therefore not recapitulated in vivo in Zfp36aa/aa mice
(Fig. 8).
DISCUSSION
The phosphorylation and dephosphorylation of TTP constitute a molecular switch
for turning gene expression on and off during responses to inﬂammatory stimuli (43).
In Dusp1/ cells, the dysregulation of MAPK p38 signaling pushes the switch in the
FIG 8 In vivo responses to LPS are broadly impaired in Zfp36aa/aa mice. Zfp36/ and Zfp36aa/aa mice were
injected intraperitoneally with 5 mg/kg LPS and humanely sacriﬁced after 3 or 12 h. Serum cytokine levels
were measured by a multiplex bead assay or an ELISA. Graphs represent means  standard errors of the
means for 5 untreated mice and 10 LPS-injected mice at each time point. *, P  0.05; **, P  0.01; ***,
P  0.005 (by a Mann-Whitney test). The IL-10 and TNF measurements (indicated by †) were previously
reported (53).
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“on” direction, promoting the phosphorylation and inactivation of TTP and enhancing
and sustaining the expression of TTP target genes by increasing mRNA stability. In
Zfp36aa/aa cells, the switch is locked in the “off” position, and the expression of TTP
target genes is diminished as a consequence of enhanced mRNA decay. This locked
switch prevents the overexpression of TTP target genes in cells in which the two
genetic modiﬁcations are combined (43, 52). Here and in previous reports (52, 53), the
expression of both TNF and IL-10 conformed exactly to the pattern described above,
whether investigated in vitro or in vivo. The behavior of these genes can be understood
simply in terms of our working model of TTP function. However, it remains puzzling at
ﬁrst sight that the same molecular mechanism is used to regulate the expressions of a
powerful proinﬂammatory cytokine and a powerful anti-inﬂammatory cytokine. It is
likely that this shared regulation contributes to the resolution of inﬂammation. Any
stimulus that provokes the strong expression of TNF via the activation of the MAPK p38
and the phosphorylation of TTP will also provoke the strong expression of IL-10, with
a built-in delay owing to the slower transcriptional activation of the latter. IL-10 then
acts as an autocrine or paracrine negative feedback regulator of the inﬂammatory
response.
When gene expression was initially studied in Zfp36aa/aa M-BMMs, we were puzzled
that IL-6 did not behave as expected. IL-6 has been well characterized as a target of TTP
(30, 55, 56), yet its expression was not consistently diminished in Zfp36aa/aa M-BMMs
and in many experiments was actually increased (Fig. 2). Microarray analysis also
revealed the surprising overexpression of several transcripts by Zfp36aa/aa M-BMMs (Fig.
1), among which Il12b was prominent. We hypothesized that an impairment of IL-10-
mediated negative feedback control contributed to these anomalies. Being a secondary
response gene, the peak of expression of Il6 occurred at a time when the endogenous
IL-10 protein had already accumulated in tissue culture supernatants (Fig. 4). IL-6
expression was sensitive to inhibition by IL-10, with a very steep dose response at
FIG 9 Regulation of cytokine expression by the DUSP1-TTP axis in vivo. Dusp1/-Zfp36/, Dusp1/-
Zfp36/, Dusp1/-Zfp36aa/aa, or Dusp1/-Zfp36aa/aa mice were injected intraperitoneally with 5 mg/kg
LPS and humanely sacriﬁced after 3 h. Spleens were excised, RNA was prepared, and the levels of the
indicated transcripts were quantiﬁed by qPCR, with normalization against B2m mRNA levels and then
against the untreated wild-type (Dusp1/-Zfp36/) control. Graphs represent means  standard errors
of the means for 2 untreated and 4 LPS-treated mice of each genotype. n.s., not statistically signiﬁcant;
**, P  0.01; ***, P  0.005 (by ANOVA).
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concentrations of between 1 and 3 ng/ml (Fig. 5), similar to the range of IL-10
concentrations produced by Zfp36/ and Zfp36aa/aa M-BMMs (Fig. 4). As predicted,
IL-6 was underexpressed by Zfp36aa/aa GM-BMMs (Fig. 6) and by Zfp36aa/aa peritoneal
macrophages (data not shown), both of which produce very low levels of IL-10.
Neutralization of IL-10 also restored the expected gene expression pattern, in which
IL-6 was underexpressed by Zfp36aa/aa M-BMMs (Fig. 7). It therefore appears that
differences in the levels of IL-10 in tissue culture have a profound effect on the
expression of the Il6 gene, resulting in variable under- or overexpression by Zfp36aa/aa
M-BMMs. Although Tnf gene expression is also negatively regulated by IL-10 (Fig. 5) (19,
61), its immediate early pattern of expression (61, 62) (Fig. 4) presumably allows it to
escape the inﬂuence of such ﬂuctuations in the efﬁcacy of negative feedback control.
By the time that levels of endogenous IL-10 accumulate signiﬁcantly, the transcriptional
activity of the Tnf gene is already declining.
The production of the IL-12p40 protein was profoundly sensitive to IL-10-mediated
inhibition (Fig. 5). The paradoxical overexpression of IL-12p40 by Zfp36aa/aa M-BMMs
was caused by an increase in transcription (Fig. 4). Like others (63, 64), we found no
evidence that TTP regulated Il12b mRNA stability (Fig. 4). This increase of expression
was not observed in Zfp36aa/aa GM-BMMs, which express little IL-10 (Fig. 6). IL-10 has
been reported to inhibit Il12b transcription via the induction of the transcriptional
repressor NFIL3 (nuclear factor, IL-3 regulated) (13). Four hours after the addition of LPS,
the expression level of Nﬁl3 mRNA was signiﬁcantly lower in Zfp36aa/aa than in
Zfp36/ M-BMMs (2,135  35 versus 4,940  497 robust microarray analysis units
[RMA]; P  0.005). It is therefore possible that impaired negative feedback via NFIL3
contributes to the enhanced transcriptional induction of the Il12b gene in Zfp36aa/aa
M-BMMs (Fig. 4). However, neutralization of IL-10 only partially reversed the overex-
pression of IL-12p40 by Zfp36aa/aa M-BMMs, suggesting that additional mechanisms
may be involved. TTP has been reported to inhibit Il12b gene expression by modulating
the function of the transcription factor NF-B (nuclear factor kappa light chain en-
hancer of activated B cells) (65). However, we were unable to detect any differences in
NF-B function in Zfp36aa/aa M-BMMs (53). Additionally, it is difﬁcult to explain the
increases in the expression levels of only a few genes by the increased activity of a
transcription factor that regulates much of the macrophage response to LPS. Therefore,
the aberrant expression of IL-12p40 by Zfp36aa/aa M-BMMs has been only partially
accounted for.
Previous reports identiﬁed IL-10 as a target of TTP (39, 41), describing the increased
expression of IL-10 and the consequent underexpression of both IL-6 and IL-12 by
Zfp36/ macrophages. The phenomenon described here is a mirror image, in which a
gain of function of TTP impairs IL-10-mediated negative feedback control in vitro and
promotes the increased expressions of these two cytokines. As we and others are
interested in the concept of therapeutic targeting of TTP (31, 43, 53), the impairment
of negative feedback control was a source of concern, prompting us to test the in vivo
effects of the gain-of-function mutation. Despite the fact that LPS-induced IL-10
expression was diminished in Zfp36aa/aa mice, we detected no corresponding increase
in the expression of either IL-6 or IL-12p40 (Fig. 8 and 9). In fact, IL-6 was consistently
expressed at very low levels by Zfp36aa/aa mice following systemic LPS challenge (Fig.
8), the injection of zymosan into dorsal air pouches, or the induction of experimental
arthritis (53). Increased circulating levels of either IL-12 or IL-23, which share the
common IL-12p40 subunit, would be expected to promote Th1 and Th17 responses,
characterized by elevated expression levels of IFN- and IL-17. In fact, both of these
effector cytokines were present at lower levels in sera of LPS-injected Zfp36aa/aa mice
(49) (Fig. 8).These ﬁndings suggest that agonists that activate TTP may exert anti-
inﬂammatory effects without incurring immune activation via the increased expression
of IL-6, IL-12, or IL-23. It will be important to test this further in experimental settings
such as inﬂammatory bowel disease, where impaired expression of IL-10 may have
profound consequences (8, 12).
A remaining question is why the behaviors of the Il6 and Il12b genes are so different
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when studied in vitro and in vivo. Although in vitro experiments are invaluable for
gaining insight into molecular mechanisms of gene regulation, it is easy to forget how
poorly they model inﬂammatory responses in vivo. In many senses, the in vitro assay
system is artiﬁcial. The population of cells is homogeneous, their exposure to stimulus
is synchronous, and they remain thereafter in a static milieu, in which local concentra-
tions of cytokines and other effectors may become high and autocrine or paracrine
effects may be ampliﬁed. In vivo, the population of cells responding to LPS is hetero-
geneous, their time of exposure to the agonist will vary somewhat, and the local
accumulation of cytokines and other immune effectors will be limited by circulation.
Whatever the explanation for the divergent behaviors of IL-6 and IL-12p40 in vitro and
in vivo, our principal conclusion remains the same. A gain of function of TTP causes the
dysregulation of IL-6 and IL-12p40, at least in part indirectly, via changes in IL-10
expression. However, aberrant overexpression of IL-6 and IL-12p40 does not occur in
Zfp36aa/aa mice.
MATERIALS AND METHODS
Materials. LPS (Escherichia coli serotype EH100) was purchased from Enzo Life Sciences. Other
biochemicals were purchased from Sigma-Aldrich unless otherwise stated. All media and sera were
routinely tested for endotoxin by using the Limulus amebocyte lysate test (Lonza) and were rejected if
the endotoxin concentration exceeded 0.1 U/ml.
Generation of mouse strains. The generation of the Zfp36aa/aa mouse strain in the C57BL/6
background was described previously (49). The Dusp1/ strain was a generous gift from Bristol-Myers
Squibb and was backcrossed to the C57BL/6 strain for 10 generations prior to performing the experi-
ments described here. The double-targeted Dusp1/-Zfp36aa/aa line was generated by three generations
of crossing, with genotyping being performed by PCR of genomic DNA, and thereafter was maintained
as a pure-breeding line. Bone marrow from Il10/ mice was generously provided by Fiona Powrie
(Oxford).
In vivo experiments and cell isolation. All animal experiments were approved by local ethical
committees and performed under UK Home Ofﬁce project licenses. C57BL/6 mice were purchased from
Harlan Laboratories. All mice used were between 6 and 12 weeks of age. To assess the systemic response
to LPS, mice were injected i.p. with 5 mg/kg of body weight of puriﬁed LPS in 200 l sterile phosphate-
buffered saline (PBS). Mice were humanely culled 3 h or 12 h after challenge, and peripheral blood was
collected by cardiac puncture for serum isolation. Spleens were excised and snap-frozen in liquid
nitrogen for later isolation of RNA.
Bone marrow was isolated from humanely culled mice, and BMMs (bone marrow-derived macro-
phages) were obtained by differentiation in vitro with either 100 ng/ml M-CSF (Peprotech), or 50 ng/ml
GM-CSF in RPMI 1640 containing 10% heat-inactivated fetal calf serum (FCS) and penicillin-streptomycin
for 7 days. BMMs were plated at a density of 1  106 macrophages/ml in the appropriate cell culture
plate at least 1 day prior to stimulation.
Neutralization of endogenous secreted IL-10 was achieved by in vitro incubation with an IL-10-
neutralizing antibody (catalogue number 501407; BioLegend) at 10 g/ml for the duration of the assays.
Controls were treated with an equal concentration of isotype-matched antibody.
Measurements of mRNA levels. RNA was extracted from BMMs by using QIAshredder columns and
an RNeasy minikit (Qiagen). cDNA was generated by using the iScript cDNA synthesis kit (Bio-Rad). Gene
expression was quantiﬁed by reverse transcription-quantitative PCR (qRT-PCR) on a LightCycler 480 II
instrument (Roche) using the Superscript III platinum RT-PCR kit and custom-synthesized oligonucleotide
primers (Euroﬁns MWG) with SYBR Premix Ex Taq (Lonza). The relative gene expression level was
calculated by using the ΔΔCT method with Gapdh or B2m mRNA for the normalization of RNA levels.
Primary transcript PCR was performed by using primer pairs that crossed exon-intron boundaries, with
an additional DNase I step to remove contaminating genomic DNA from RNA samples (Qiagen). Control
PCRs were carried out in the absence of RT in order to monitor genomic DNA contamination, which in
all cases was negligible. Sequences of oligonucleotides designed to detect primary or mature transcripts
are available from the authors upon request.
The half-life of mRNA was estimated by using the transcription inhibitor actinomycin D (Sigma) at 5
g/ml, followed by measurement of mRNA levels by quantitative real-time PCR.
Microarray analyses were performed by using SurePrint G3 Mouse GE 8x60K slides (Agilent) and
Partek Genomics Suite version 6.6, build 6.13.0315 (Partek), as previously described (49). For the
generation of volcano plots, transcripts were ﬁrst ﬁltered for signiﬁcant upregulation in response to LPS
(2-fold increase; adjusted P value of 0.05), and weakly expressed transcripts were removed by the
application of an arbitrary ﬁlter of 200 RMA. Plots (log2 fold difference of expression versus log10
analysis of variance [ANOVA] P value) were constructed by using ggplot2s in the R statistical package,
with subset cutoffs at a P value of 0.05 and a fold difference of expression of 1.5.
Assessment of protein expression. Secreted factors in tissue culture supernatants and sera were
quantiﬁed by an ELISA according to the manufacturer’s instructions (eBioscience) or by using Bio-Plex
bead capture assays and a Bio-Plex 200 analyzer (Bio-Rad).
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Statistical analysis. GraphPad Prism software (version 5.03) was used for statistical analysis. A
Mann-Whitney U test was used for comparisons of two groups. For analysis of multiple groups, ANOVA
with Bonferroni correction for multiple comparisons was used.
Accession number. Microarray data discussed in this paper were deposited at the Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) with accession number GSE68449.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/MCB
.00536-16.
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